tiprankstipranks
Trending News
More News >

Broncus Holding Corp. Gains Approval for Innovative Lung Cancer Treatment System in China

Story Highlights
Broncus Holding Corp. Gains Approval for Innovative Lung Cancer Treatment System in China

Don’t Miss TipRanks’ Half-Year Sale

Broncus Holding Corp. ( (HK:2216) ) has provided an announcement.

Broncus Holding Corporation has announced that its BroncAblate® Lung Radiofrequency Ablation Generator has been approved for marketing in China by the National Medical Products Administration. This approval marks a significant step for the company as it begins the commercialization of the world’s first natural orifice transluminal radiofrequency ablation system for lung cancer. The system, which combines the BroncAblate® Generator and Catheter, offers a less invasive treatment option for lung tumors, potentially improving patient outcomes with fewer complications. This development positions Broncus Holding Corporation as a pioneer in the field of interventional lung cancer therapies, filling a global gap with its innovative approach.

More about Broncus Holding Corp.

Broncus Holding Corporation operates in the medical technology industry, focusing on innovative interventional devices for lung cancer treatment. The company’s primary product is the BroncAblate® Lung Radiofrequency Ablation System, which includes a generator and catheter designed for minimally invasive lung cancer treatment.

Average Trading Volume: 6,751,606

Technical Sentiment Signal: Buy

Current Market Cap: HK$1.09B

See more data about 2216 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1